Meeting
2017 ASCO Annual Meeting
Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.
Authors
Naval Guastad Daver
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Naval Guastad Daver , Sreyashi Basu , Guillermo Garcia-Manero , Jorge E. Cortes , Farhad Ravandi , Elias Jabbour , Stephany Hendrickson , Mark Brandt , Sherry Pierce , Tauna Gordon , Naveen Pemmaraju , Michael Andreeff , Jing Ning , Steven Kornblau , Tapan M. Kadia , Courtney Denton Dinardo , Marina Konopleva , James Patrick Allison , Hagop M. Kantarjian , Padmanee Sharma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT02397720
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7026)
DOI
10.1200/JCO.2017.35.15_suppl.7026
Abstract #
7026
Poster Bd #
226
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study.
First Author: Hussein Abbas
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Role for immune checkpoint blockade in BRCA2-mutant prostate cancer.
First Author: Anshuman Panda
Poster
2018 ASCO Annual Meeting
Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML.
First Author: Patrick Williams
Poster
2017 ASCO Annual Meeting
Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8+ T cells in ovarian cancer.
First Author: Stephanie Gaillard